B Cell Receptor Signaling in Receptor Editing and Leukemia

Total Page:16

File Type:pdf, Size:1020Kb

B Cell Receptor Signaling in Receptor Editing and Leukemia B CELL RECEPTOR SIGNALING IN RECEPTOR EDITING AND LEUKEMIA A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY LAURA BAILEY RAMSEY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY MICHAEL A. FARRAR, ADVISER JULY 2009 © Laura Bailey Ramsey 2009 i Acknowledgements I would like to thank my family and friends for all their support, for without it I would not have accomplished all that I have. I would especially like to thank my husband Colin, for supporting me through the tough times and celebrating with me during the happy times. I am eternally grateful to my parents and grandparents for their support and unconditional love. These last five years would not have been the same without the support of my “Minnesota Mom,” Lyn Glenn. They have all encouraged me to accomplish my dreams, and without them I would not have been able to do it. I would like to thank the Behrens lab for all their support and patience with me when I started graduate school. They introduced me to the world of immunology and B cells, and for that I am forever grateful. Tim Behrens was a great mentor and project director for the first two years of my graduate career. Brian Schram and Keli Hippen were especially helpful in teaching me all about B cells. Jason Bauer, Thearith Koeuth, and Emily Gillespie have taught me many things about microarrays and continue to support me at the University of Minnesota. Jessica Oehrlein and Amanda Vegoe took wonderful care of my mice. Ward Ortmann and Karl Espe provided much needed technical support. The Farrar lab welcomed me warmly after Tim’s departure. I am especially grateful to Mike for learning a new project and providing good advice and support. Lynn Heltemes-Harris and Mark Willette provided much of the data for Chapter 4, and without their hard work dissecting tumor mice this thesis would be incomplete. Linxi Li and Casey Katerndahl provided helpful discussions as fellow members of the B cell group in the lab. Matt Burchill provided support and advice on this thesis even after leaving the lab. I would like to thank Jianying Yang, Bao Vang, and Shawn Mahmud for helpful discussions, despite the fact that they are “T cell people.” My mice were well taken care of by Amanda Vegoe, Rachel Agneberg, Christine Andersen and Josh Bednar. I am grateful to everyone in the Farrar lab for their friendship and support. I would like to thank other members of the Center for Immunology for their support and advice. James McLachlan provided excellent advice on this thesis and post-doctoral interview preparation. Colleen Winstead provided moral support in the library during the writing of this thesis. Paul Champoux and Nisha Shah provided cell sorting support and flow cytometry expertise. I am grateful to my committee for their guidance and support. The Molecular, Cellular, Developmental Biology & Genetics staff provided support throughout my graduate career, especially during the transition period from one lab to another. I am also grateful to the graduate school for funding through the Doctoral Dissertation Fellowship. I am thankful for my fellow graduate students in the MCDB&G program for moral support and many wonderful friendships that will undoubtedly last a lifetime. They have made my graduate career enjoyable and provided many memorable experiences. ii Dedication This dissertation is dedicated to everyone who has supported me during the past five years while I attended graduate school. I love you all! iii Abstract There are many unanswered questions in the B cell field, but one of paramount importance is how B cells are tolerized to avoid autoimmunity. The majority of developing B cells are probably self-reactive, and many that make it through B cell development to the periphery show evidence of receptor editing. The question remains as to how the B cells signal to re-induce the editing machinery, whether it is a positive reactivation signal or the release of an inhibitory tonic signal. We propose that it is the release of a tonic signal through the B cell receptor that inhibits recombination when the BCR is present on the surface, but when the BCR binds self-antigen it is internalized, the inhibitory signal is abrogated, and the recombination machinery is reactivated. We tested this hypothesis using several transgenic models, including RAG2-GFP mice, HEL Ig mice, and anti-κ mice. We also used several mice deficient in BCR signaling to test this hypothesis, and found that reduced BCR signaling induces more receptor editing. When we tested mice with excessive BCR signaling or pharmacologically mimicked the BCR signal, we found a decrease in receptor editing. These experiments provide compelling evidence for the inhibitory tonic signaling hypothesis and against the activation signaling hypothesis. Another question unanswered in the B cell field is how B cells are transformed into leukemia and lymphoma. There have been whole genome analysis studies to show that genes involved in the BCR signaling pathway are involved in many B cell malignancies, including leukemia, lymphoma and myeloma. Our studies in mice provide evidence that in combination with constitutive STAT5 activation, a loss of genes involved in B cell development (ebf1 and pax5) or pre-BCR signaling (blnk, iv PKCβ, and btk) results in leukemia. These are genes that have been shown to be deleted in B cell acute lymphoblastic leukemia (ALL). We also demonstrate an increase the phospho-STAT5 levels in adult BCR-ABL+ ALL patients. Herein we have developed a new mouse model for B-ALL that may be useful in testing and perfecting treatment protocols used on ALL patients. v Table of Contents List of tables vi List of figures vii Author/publication information ix List of abbreviations x Chapter 1. Introduction 1 B cell Development 1 Transcriptional Control of B cell Development 3 Interleukin-7 Receptor Signaling 5 V(D)J Recombination 7 Pre-BCR Signaling 9 BCR Signaling 13 Receptor Editing 18 B cell Acute Lymphoblastic Leukemia 22 Objectives 26 Chapter 2. BCR Basal Signaling Regulates Antigen-Induced Ig Light Chain 36 Rearrangements Chapter 3. Tonic BCR Signaling Represses Receptor Editing via the Ras 87 and Calcium Signaling Pathways Chapter 4. STAT5 Cooperates with Defects in B Cell Development to Initiate 113 Progenitor B Cell Leukemia Chapter 5. Discussion 166 References 172 Appendix: Permission letter from the Journal of Immunology 187 vi List of Tables Chapter 2. Table 1. Selected differentially expressed transcripts in Ag-treated 85 immature B cells. Chapter 4. Table I. The top 50 probe sets by fold change (Ia) or p-value (Ib) 163 vii List of Figures Chapter 1. Figure 1. B cell development 28 Figure 2. Transcription Factor Network Involved in B cell Development 30 Figure 3. B cell Receptor Signaling Pathway 32 Figure 4. V(D)J Recombination & LC Receptor Editing 34 Chapter 2. Figure 1. Xid Immature B cells show impaired antigen-induced 69 activation responses, but normal IgM downregulation Figure 2. RAG2-GFP responses in xid and lynnull immature B cells 71 Figure 3. Relationship between RAG2-GFP expression and surface IgM 73 Figure 4. Back-differentiation of antigen-stimulated immature B cells 75 Figure 5. Expression of immature B cell markers following IL-7 77 bone marrow culture Figure 6. Antigen-treated immature B cells show similar gene 79 expression profiles as cells that have lost the BCR or have been treated with a tyrosine kinase inhibitor Figure 7. Suppression of RAG2-GFP and Ig rearrangements in 81 immature B cells by PMA and Ionomycin Figure 8. Pre-B cell LC editing to membrane self-antigen is inhibited 83 by PMA/Ionomycin viii Chapter 3 Figure 1. Light chain expression in BM chimeras 107 Figure 2. Editing ratio in BM chimeras 109 Figure 3. Model of Receptor Editing Inhibition by BCR Signals 111 Chapter 4 Figure 1. Spontaneous tumors in STAT5b-CA mice 132 Figure 2. Cyclin D2 and myc expression in STAT5b-CA ALL 134 Figure 3. STAT5b-CA causes a significant increase in tumor incidence 136 in all mouse crosses Figure 4. Flow cytometric analysis of leukemic mice 138 Figure 5. CD79a expression 140 Figure 6. Microarray analysis of tumor samples 142 Figure 7. Canonical pathways differentially regulated in tumor samples 144 Figure 8. Expression of BCR signaling pathway genes 148 Figure 9. TNFR expression 151 Figure 10. Regulators of NFkB2 signaling 153 Figure 11. Cooperation response genes in STAT5b-CA x xid tumors 155 Figure 12. Total STAT5 protein expression 157 Figure 13. STAT5 activation in human ALL 159 Figure 14. STAT5 phosphorylation in different cytogenetic subsets of ALL 161 ix Author/Publication Information Chapter 2. BCR Basal Signaling Regulates Antigen-Induced Ig Light Chain Rearrangements Published in the April 1, 2008 issue of the Journal of Immunology (J Immunol. 2008 Apr 1;180(7):4728-41). I wrote much of the manuscript, re-analyzed data and prepared several of the figures, submitted the manuscript, responded to reviewers’ comments and made necessary revisions. Brian Schram and Lina Tze performed experiments, analyzed data, prepared figures and assisted in writing the manuscript. Jiabin Liu, Lydia Najera, Amanda Vegoe, and Keli Hippen assisted with experiments and provided discussion related to the manuscript. Richard R. Hardy provided samples for microarray analysis. Timothy Behrens and Michael Farrar co-directed the project. Chapter 3. Tonic BCR Signaling Represses Receptor Editing via the Ras and Calcium Signaling Pathways This manuscript is in preparation for submission. I performed the experiments, analyzed the data, prepared the figures, and wrote the manuscript. Amanda Vegoe helped dissect the mice and oversaw the mouse husbandry. Timothy Behrens conceptualized the project, which was directed by Michael Farrar.
Recommended publications
  • NIH Public Access Author Manuscript Immunogenetics
    NIH Public Access Author Manuscript Immunogenetics. Author manuscript; available in PMC 2013 August 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Immunogenetics. 2012 August ; 64(8): 647–652. doi:10.1007/s00251-012-0626-0. A VpreB3 homologue from a marsupial, the gray short-tailed opossum, Monodelphis domestica Xinxin Wang, Zuly E. Parra, and Robert D. Miller Center for Evolutionary & Theoretical Immunology, Department of Biology, University of New Mexico, Albuquerque, NM, 87131, USA Robert D. Miller: [email protected] Abstract A VpreB surrogate light (SL) chain was identified for the first time in a marsupial, the opossum Monodelphis domestica. Comparing the opossum VpreB to homologues from eutherian (placental mammals) and avian species supported the marsupial gene being VpreB3. VpreB3 is a protein that is not known to traffic to the cell surface as part of the pre-B cell receptor. Rather, VpreB3 associates with nascent immunoglobulin (Ig) chains in the endoplasmic reticulum. Homologues of other known SL chains VpreB1, VpreB2, and λ5, which are found in eutherian mammals, were not found in the opossum genome, nor have they been identified in the genomes of non-mammals. VpreB3 likely evolved from earlier gene duplication, independent of that which generated VpreB1 and VpreB2 in eutherians. The apparent absence of VpreB1, VpreB2, and λ5 in marsupials suggests that an extra-cellular pre-B cell receptor containing SL chains, as it has been defined in humans and mice, may be unique to eutherian mammals. In contrast, the conservation of VpreB3 in marsupials and its presence in non-mammals is consistent with previous hypotheses that it is playing a more primordial role in B cell development.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • A Second Gene, Vpreb in the X5 Locus of the Mouse, Which Appears to Be Selectively Expressed in Pre-B Lymphocytes
    The EMBO Journal vol.6 no.8 pp.2267-2272, 1987 A second gene, VpreB in the X5 locus of the mouse, which appears to be selectively expressed in pre-B lymphocytes Akira Kudo and Fritz Melchers respectively. Exon I shows no strong homology to any known Basel Institute for Immunology, Postfach, CH-4058 Grenzacherstrasse 487, gene. The putative protein encoded by the X5 gene, although not Basel, Switzerland yet identified, is a potential candidate for heterodimer formation Communicated by F.Melchers with IgH chains and thereby, may influence the function which H chains play in pre-B cell development. We describe here, The murine gene X5 is selectively expressed in pre-B lym- 4.6 kb upstream of X5 another gene named VpreB1 composed of phocytes. Of the three exons encoding X5, exons II and III two exons which is selectively expressed in pre-B cell lines as show strong homologies to immunoglobulin X light (L) chain 0.85 kb mRNA. The putative protein encoded by this gene is gene segments, i.e. to Jx intron and exon, and Cx exon se- a potential candidate for association with the X5 protein and quences respectively. We have now found, 4.6 kb upstream may, therefore, also influence the role of H chains in pre-B cell of X5, another gene composed of two exons which is selec- development. tively expressed in pre-B cell lines as a 0.85 kb mRNA poten- tially coding for a protein of 142 amino acids including a 19 Results amino acid-long signal peptide.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • The Role of Fc Gamma Receptors in the Activity of Therapeutic Monoclonal Antibodies
    UNIVERSITY OF SOUTHAMPTON FACULTY OF MEDICINE Cancer Sciences Unit Volume 1 of 1 The Role of Fc Gamma Receptors in the Activity of Therapeutic Monoclonal Antibodies by Robert James Oldham Thesis for the degree of Doctor of Philosophy September 2016 UNIVERSITY OF SOUTHAMPTON ABSTRACT FACULTY OF MEDICINE Biomedicine Thesis for the degree of Doctor of Philosophy THE ROLE OF FC GAMMA RECEPTORS IN THE ACTIVITY OF THERAPEUTIC MONOCLONAL ANTIBODIES Robert James Oldham Fc gamma receptors (FcγRs) are the major family of receptors responsible for interacting with immunoglobulin G (IgG). They are known to be required for the anti-tumour activity of direct targeting mAbs through expression on NK cells and macrophages. Furthermore, recent work has suggested that cross-linking via FcγRs is required for the activity of agonistic, immune modulatory mAb. This thesis sought to investigate the requirement for these receptors for different aspects of mAb activity; from T cell activation to tumour depletion, using a combination of in vitro and in vivo systems. A panel of CHO-K1 cells were generated and transfected to express the polymorphic variants of human FcγRs. These were characterised for their ability to bind IgG before being used as feeder cells in T cell proliferation assays. The assays found that cross-linking of the anti-CD28 mAb, TGN1412 by FcγRIIb (CD32b) or FcγRIIa (CD32a) but not FcγRIIIa (CD16a) transfected cells induced T cell proliferation. Furthermore, this was accompanied by the release of pro-inflammatory cytokines including TNF-α, IFN-γ and IL-2. With the importance of cross-linking via CD32b demonstrated, experiments probed the mechanism of expression using Ramos and Raji cells.
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • Cloning and Characterization of Ovine Immunoglobulin G Fc Receptor II (Fcgrii)§ Veterinary Immunology and Immunopathology
    Veterinary Immunology and Immunopathology 133 (2010) 243–249 Contents lists available at ScienceDirect Veterinary Immunology and Immunopathology journal homepage: www.elsevier.com/locate/vetimm Short communication Cloning and characterization of ovine immunoglobulin G Fc receptor II (FcgRII)§ Yunchao Liu a,b, Aiping Wang b, Songlin Qiao a, Gaiping Zhang a,*, Jun Xi a, Leiming You a, Xiaohui Tian a, Qiaomu Li a, Lina Zhang a, Junqing Guo a a Key Laboratory of Animal Immunology of the Ministry of Agriculture, Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou 450002, China b College of Bioengineering, Zhengzhou University, Zhengzhou 450001, China ARTICLE INFO ABSTRACT Article history: Immunoglobulin G (IgG) Fc receptors (FcgRs) bind to immune complexes through Received 31 December 2008 interactions with the Fc region of IgG to initiate or inhibit the defense mechanism of the Received in revised form 1 July 2009 leukocytes on which they are expressed. In this study, we describe the cloning, sequencing Accepted 9 July 2009 and characterization of ovine FcgRII. By screening a translated expression sequence tag (EST) database with the protein sequence of bovine IgG Fc receptor II, we identified a Keywords: putative ovine homologue. Using rapid amplification of cDNA ends (RACE), we isolated the Sheep cDNA encoding ovine FcgRII from peripheral blood leucocyte RNA. The ovine FcgRII cDNA FcgRII contains an 894 bp open-reading frame, encoding a 297 amino acid transmembrane Inhibitory receptor Expression glycoprotein composed of two immunoglobulin-like extracellular domains, a transmem- brane region and a cytoplasmic tail with an immunoreceptor tyrosine-based inhibitory motif (ITIM).
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Molecular and Cellular Studies Examining the Biological Significance of Different Isoforms of the Receptor Tyrosine Kinase' C-Kit
    Molecular and cellular studies examining the biological significance of different isoforms of the receptor tyrosine kinase' c-Kit Antony Charles Cambareri B. Sc. (Hons) Institute of Medical and Veterinary Science Department of Medicine University of Adelaide South Australia A thesis submitted to the University of Adelaide in candidature for the degree of Doctor of Philosophy October 2004 Declaration This thesis contains no material that has been accepted for the award of any other degree or diploma in any other university. To the best of my knowledge and belief' this thesis contains no material previously published or written by another person' except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopylng. p? Antony C atefl 4 ,(? ll Acknowledgments I would like to sincerely thank my supervisors, Professor Leonie Ashman and professor Bik To. I thank them both for their encouragement, persistence and support over the period of this work' Special thanks to Steve Fitter, who was pivotal in "retraining" me in the art of science upon my return to the lab from "the dark side". He is both a great friend and a legendary molecular biologist (it is true that it will work if you add a microlitre!)' I also thank Andrew Zannettino for spending the time to critique drafts of this thesis, and for valuable input to experimental design. I acknowledge the valuable technical assistance of Ly Nguyen and Peter Konstantopolous from the Leukaemia Haemopoiesis Laboratory. Thanks also to Sue Branford and Rebecca Lawrence for their assistance with Quantitative PCR.
    [Show full text]
  • Signaling Pathways in the Male Rat Bone Dharani M
    Physiological Reports ISSN 2051-817X ORIGINAL RESEARCH Different exercise modalities have distinct effects on the integrin-linked kinase (ILK) and Ca2+ signaling pathways in the male rat bone Dharani M. Sontam1,2, Elwyn C. Firth1,2,3, Peter Tsai4, Mark H. Vickers1,2 & Justin M. O’Sullivan1,2 1 The Liggins Institute, University of Auckland, Auckland, New Zealand 2 Gravida: National Centre for Growth and Development, University of Auckland, Auckland, New Zealand 3 Department of Sport and Exercise Science, University of Auckland, Auckland, New Zealand 4 School of Biological Sciences, University of Auckland, Auckland, New Zealand Keywords Abstract Cortical bone, exercise, gene expression, mechanotransduction, RNA-Seq. Mechanical loading is essential to maintain optimal skeletal health. Despite the fact that early-life exercise has positive, long-lasting effects on the mus- Correspondence culo-skeletal system, the response of the musculo-skeletal system to sponta- Elwyn C. Firth, Liggins Institute, 85 Park neous low-impact exercise has been poorly studied. Previously, we identified Road, Grafton, Auckland 1023, New subtle morphological changes in the femoral diaphysis of exercised animals Zealand. compared to nonexercised controls. We hypothesized that significant changes Tel: +64-9-923-6856 Fax: +64-9-373-8763 in gene expression of cells should precede significant measurable phenotypic E-mail: e.fi[email protected] changes in the tissues of which they are part. Here, we employed RNA-Seq to and analyse the transcriptome of the cortical bone from the femoral mid-diaphysis Justin M. O’Sullivan, Liggins Institute, 85 Park of prepubertal male Sprague-Dawley rats that were assigned to control Road, Grafton, Auckland 1023, New (CON); bipedal stance (BPS); or wheel exercise (WEX) groups for 15 days.
    [Show full text]
  • Genetic Defects in B-Cell Development and Their Clinical Consequences H Abolhassani,1,2 N Parvaneh,1 N Rezaei,1 L Hammarström,2 a Aghamohammadi1
    REVIEWS Genetic Defects in B-Cell Development and Their Clinical Consequences H Abolhassani,1,2 N Parvaneh,1 N Rezaei,1 L Hammarström,2 A Aghamohammadi1 1Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran 2Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden n Abstract Expression of selected genes in hematopoietic stem cells has been identified as a regulator of differentiation of B cells in the liver and bone marrow. Moreover, naïve B cells expressing surface immunoglobulin need other types of genes for antigen-dependent development in secondary lymphoid organs. Many advanced molecular mechanisms underlying primary antibody deficiencies in humans have been described. We provide an overview of the mutations in genes known to be involved in B-cell development and their clinical consequences. Key words: Genetic disorder. B-cell development. Primary antibody deficiencies. Clinical phenotypes. n Resumen Se ha identificado la expresión de genes seleccionados en las células pluripotenciales de médula ósea como reguladores de la diferenciación de las células B en el hígado y en médula ósea. Sin embargo, las células B naïve que expresan inmunoglubulinas de superficie, necesitan otros tipos de genes para su desarrollo en los órganos linfoides secundarios dependienteS de antígeno. Se han descrito muchos mecanismos moleculares avanzados que subrayan las inmunodeficiencias en humanos y esta revisión constituye una visión general de la mutación en todos los genes conocidos involucrados en el desarrollo de las células B y sus consecuencias clínicas. Palabras clave: Alteraciones genéticas. Desarrollo de las células B.
    [Show full text]
  • Supplementary Data ASXL2 Regulates Hematopoiesis in Mice and Its
    Supplementary data ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion Supplementary Methods Genomic DNA extraction Genomic DNA was extracted from BM mononuclear cells using a DNA extraction kit (Puregene Gentra System, Minneapolis, MN, USA) according to the manufacturer’s instructions. Genomic DNA was quantified using Qubit Fluorometer (Life Technologies) and DNA integrity was assessed by agarose gel electrophoresis. For samples with low quantity, DNA was amplified using REPLI-g Ultrafast mini kit (Qiagen). Peripheral blood analysis Complete peripheral blood counts were analysed using Abbott Cell-Dyn 3700 hematology analyzer (Abbott Laboratories). Expression analysis of Asxl2 and Asxl1 Transcript levels of Asxl2 and Asxl1 were estimated using quantitative RT-PCR with following primers: Asxl2 primer set 1, ATTCGACAAGAGATTGAGAAGGAG (forward) and TTTCTGTGAATCTTCAAGGCTTAG (reverse); Asxl2 primer set 2, GCCCTTAACAATGAGTTCTTCACT (forward) and TCCACAGCTCTACTTTCTTCTCCT (reverse); Asxl1 primers, GGTGGAACAATGGAAGGAAA (forward) and CTGGCCGAGAACGTTTCTTA (reverse). Asxl2 protein was detected in immunoblot using anti-ASXL2 antibody (Bethyl). In vitro differentiation of bone marrow cells Bone marrow (BM) cells were cultured in IMDM containing 20% FBS and 10 ng/ml IL3, 10 ng/ml IL6, 20 ng/ml SCF and 20 ng/ml GMCSF for two weeks. For FACS analysis, cells were washed, stained with fluorochrome-conjugated antibodies and analysed on FACS LSR II flow cytometer (BD Biosciences) using FACSDIVA software (BD Biosciences). Colony re-plating assay Bone marrow cells were plated in methylcellulose medium containing mouse stem cell factor (SCF), mouse interleukin 3 (IL-3), human interleukin 6 (IL-6) and human erythropoietin (MethoCult GF M3434; StemCell Technologies). Colonies were enumerated after 9-12 days and cells were harvested for re-plating.
    [Show full text]